We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biodegradable Microneedle Patch Automates Tuberculosis Skin Testing

By LabMedica International staff writers
Posted on 04 Sep 2013
Print article
Image: A chitin microneedle patch tested on human skin (Photo courtesy of the University of Washington).
Image: A chitin microneedle patch tested on human skin (Photo courtesy of the University of Washington).
Image: Comparison of a microneedle tuberculosis test with a traditional test administered with a hypodermic needle. The lower images show needle-depth problems that can occur with the conventional test (Photo courtesy of the University of Washington).
Image: Comparison of a microneedle tuberculosis test with a traditional test administered with a hypodermic needle. The lower images show needle-depth problems that can occur with the conventional test (Photo courtesy of the University of Washington).
A patch comprising biodegradable microneedles has been developed that may replace the classical hypodermic needle tuberculin diagnostic test for tuberculosis.

The standard diagnostic test for tuberculosis (termed the Mantoux technique) is based on an intradermal injection of tuberculin, which is a species-nonspecific glycerol extract of the tubercle bacillus obtained from filtrates of sterilized, concentrated cultures. A person who has been exposed to tuberculosis bacteria is expected to mount an immune response in the skin containing the bacterial proteins. The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters.

However, the standard diagnostic test is difficult to perform, since obtaining a correct diagnosis depends on the hypodermic needle being inserted into the arm of the patient at a precise angle and depth.

Investigators at the University of Washington (Seattle, USA) recently reported development of a technique that promises to be a significant improvement to the Mantoux technique. They created a patch containing biodegradable chitin microneedles. Each needle is 750 micrometers long and is coated with tuberculin solution.

The patch test was evaluated on guinea pigs, and results showed that following insertion of the microneedles, the positive skin reaction associated with having a tuberculosis infection was identical to that obtained when using the standard hypodermic needle test.

"It is like putting on a bandage," said senior author Dr. Marco Rolandi, assistant professor of materials science and engineering at the University of Washington. "As long as the patch is applied on the skin, the test is always delivered to the same depth underneath the skin. With a microneedle test there is little room for user error, because the depth of delivery is determined by the microneedle length rather than the needle-insertion angle. This test is painless and easier to administer than the traditional skin test with a hypodermic needle."

The guinea pig study was published in the August 26, 2013, online edition of the journal Advanced Healthcare Materials.

Related Links:
University of Washington


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.